company background image
4743 logo

Oneness Biotech TPEX:4743 Stock Report

Last Price

NT$153.00

Market Cap

NT$69.4b

7D

5.2%

1Y

-27.8%

Updated

26 Apr, 2024

Data

Company Financials +

Oneness Biotech Co., Ltd.

TPEX:4743 Stock Report

Market Cap: NT$69.4b

4743 Stock Overview

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan.

4743 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Oneness Biotech Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oneness Biotech
Historical stock prices
Current Share PriceNT$153.00
52 Week HighNT$253.50
52 Week LowNT$144.00
Beta1.52
1 Month Change-12.07%
3 Month Change-13.31%
1 Year Change-27.77%
3 Year Change-26.24%
5 Year Change500.26%
Change since IPO1,049.34%

Recent News & Updates

Recent updates

Announcing: Oneness Biotech (GTSM:4743) Stock Soared An Exciting 936% In The Last Three Years

Mar 01
Announcing: Oneness Biotech (GTSM:4743) Stock Soared An Exciting 936% In The Last Three Years

Shareholder Returns

4743TW PharmaceuticalsTW Market
7D5.2%-1.0%-2.3%
1Y-27.8%6.9%27.2%

Return vs Industry: 4743 underperformed the TW Pharmaceuticals industry which returned 6.9% over the past year.

Return vs Market: 4743 underperformed the TW Market which returned 27.2% over the past year.

Price Volatility

Is 4743's price volatile compared to industry and market?
4743 volatility
4743 Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement3.8%
Market Average Movement4.7%
10% most volatile stocks in TW Market8.7%
10% least volatile stocks in TW Market2.2%

Stable Share Price: 4743 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4743's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008n/aChih-Hui Chengwww.onenessbio.com

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials.

Oneness Biotech Co., Ltd. Fundamentals Summary

How do Oneness Biotech's earnings and revenue compare to its market cap?
4743 fundamental statistics
Market capNT$69.40b
Earnings (TTM)-NT$1.31b
Revenue (TTM)NT$86.78m

799.6x

P/S Ratio

-52.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4743 income statement (TTM)
RevenueNT$86.78m
Cost of RevenueNT$54.22m
Gross ProfitNT$32.56m
Other ExpensesNT$1.35b
Earnings-NT$1.31b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.89
Gross Margin37.52%
Net Profit Margin-1,512.82%
Debt/Equity Ratio0%

How did 4743 perform over the long term?

See historical performance and comparison

Dividends

0.06%

Current Dividend Yield

-3%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.